Top

BMC Neurology

Published in:

01-12-2020 | Antidepressant Drugs | Research article

Percutaneous mastoid electrical stimulator improves Poststroke depression and cognitive function in patients with Ischaemic stroke: a prospective, randomized, double-blind, and sham-controlled study

Authors: Taoli Lu, Lanying He, Bei Zhang, Jian Wang, Lili Zhang, Wei Wei Dong, Hao Yang

Published in: BMC Neurology | Issue 1/2020

Abstract

Background

Poststroke depression can lead to functional dependence, cognitive impairment and reduced quality of life. The aim of this study was to evaluate the effects of a percutaneous mastoid electrical stimulator (PMES) plus antidepressants on poststroke depression and cognitive function.

Methods

This study was a prospective, randomized, double-blind, and sham-controlled study. A total of 258 clinically depressed ischaemic stroke patients within 14 days of index stroke were randomly assigned to the PMES plus antidepressant (PMES group, N = 125) and sham plus antidepressant (sham group, N = 133) groups. All patients underwent the Montreal Cognitive Assessment (MoCA) and Hamilton Rating Scale for Depression (HRSD) test at 2 weeks (baseline), and 6 months(M6) after ischaemic stroke. Primary outcomes were the percentage of patients showing a treatment response (≥50% reduction in HRSD score) and depression remission (HRSD score ≤ 9) at 6 months. The secondary outcome was the percentage of patients with a MoCA score < 26.

Results

The percentages of patients showing a treatment response and depression remission were significantly higher in the PMES group than in the sham group (57.60% vs 41.35%, P = 0.009; 44.00% vs 29.32%, P = 0.014 respectively). The mean value of the HRSD score change [M (month)6-baseline] was significantly higher in the PMES group than in the sham group at 6 months (− 11.93 ± 5.32 vs − 10.48 ± 6.10, P = 0.036, respectively). The percentage of patients with MoCA scores < 26 was lower in the PEMS group than in the sham group (12.0% vs 24.06%, P = 0.012,respectively), and the mean value of the MoCA score change (M6-baseline) was higher in the PMES group than in the sham group (3.50 ± 2.55 vs 2.72 ± 2.52, P = 0.005, respectively).

Conclusion

These findings demonstrate that PMES adjunctive to antidepressant therapy is effective in reducing depression, achieving remission in the short term, and improving cognition.

Trial registration

This trial was retrospectively registered (registration number: ChiCTR1800016463) on 03 June 2018.

Stein LA, Goldmann E, Zamzam A, Luciano JM, Messé SR, Cucchiara BL, Kasner SE, Mullen MT. Association between anxiety, depression, and post-traumatic stress disorder and outcomes after ischemic stroke. Front Neurol. 2018;9:890. https://doi.org/10.3389/fneur.2018.00890 eCollection 2018.CrossRefPubMedPubMedCentral

Towfighi A, Ovbiagele B, El Husseini N, Hackett ML, Jorge RE, Kissela BM, Mitchell PH, Skolarus LE, Whooley MA, Williams LS. American Heart Association stroke council; council on cardiovascular and stroke nursing; and council on quality of care and outcomes research. Poststroke depression:a scientific statement for healthcare professionals from the American Heart Association/American stroke association. Stroke. 2017;48(2):e30–43. https://doi.org/10.1161/STR.0000000000000113.CrossRefPubMed

Love MF, Sharrief A, Chaoul A, Savitz S, Beauchamp JES. Mind-body interventions, psychological stressors, and quality of life in stroke survivors. Stroke. 2019;50(2):434–40. https://doi.org/10.1161/STROKEAHA.118.021150.CrossRefPubMed

Huang J, Zhou FC, Guan B, Zhang N, Wang A, Yu P, Zhou L, Wang CY, Wang C. Predictors of remission of early-onset Poststroke depression and the interaction between depression and cognition during follow-up. Front Psychiatry. 2019;9:738. https://doi.org/10.3389/fpsyt.2018.00738 eCollection 2018.CrossRefPubMedPubMedCentral

De RA, Fransen E, Brouns R, Geurden M, Peij D, Mariën P, De Deyn PP, Engelborghs S. Poststroke depression and its multifactorial nature: results from a prospective longitudinal study. J Neurol Sci. 2014;347(1–2):159–66. https://doi.org/10.1016/j.jns.2014.09.038.CrossRef

Choi-Kwon S, Han SW, Kwon SU, Kang DW, Choi JM, Kim JS. Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. Stroke. 2006;37(1):156–61. https://doi.org/10.1161/01.STR.0000190892.93663.e2.CrossRefPubMed

FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet. 2019;393(10168):265–74. https://doi.org/10.1016/S0140-6736(18)32823-X.CrossRef

Villa RF, Ferrari F, Moretti A. Post-stroke depression: Mechanisms and pharmacological treatment. Pharmacol Ther. 2018;184:131–44. https://doi.org/10.1016/j.pharmthera.2017.11.005.CrossRefPubMed

Karaiskos D, Tzavellas E, Spengos K, Vassilopoulou S, Paparrigopoulos T. Duloxetine versus citalopram and sertraline in the treatment of poststroke depression, anxiety, and fatigue. J Neuropsychiatry Clin Neurosci. 2012;24(3):349–53. https://doi.org/10.1176/appi.neuropsych.11110325.CrossRefPubMed

10.

Kohen R, Cain KC, Buzaitis A, Johnson V, Becker KJ, Teri L, Tirschwell DL, Veith RC, Mitchell PH. Response to psychosocial treatment in poststroke depression is associated with serotonin transporter polymorphisms. Stroke. 2011;42(7):2068–70. https://doi.org/10.1161/strokeaha.110.611434.CrossRefPubMedPubMedCentral

11.

Mitchell PH, Veith RC, Becker KJ, Buzaitis A, Cain KC, Fruin M, Tirschwell D, Teri L. Brief psychosocial-behavioral intervention with antidepressant reduces poststroke depression significantly more than usual care with antidepressant: living well with stroke: randomized, controlled trial. Stroke. 2009;40(9):3073–8. https://doi.org/10.1161/STROKEAHA.109.549808.CrossRefPubMedPubMedCentral

12.

Reis DJ, Kobylarz K, Yamamoto S, Golanov EV. Brief electrical stimulation of cerebellar fastigial nucleus conditions long-lasting salvage from focal cerebral ischemia: Conditioned central neurogenic neuroprotection. Brain Res. 1998;780(1):161–5 PMID:9497093.CrossRef

13.

Wang J, Dong WW, Zhang WH, Zheng J, Wang X. Electrical stimulation of cerebellar fastigial nucleus: mechanism of neuroprotection and prospects for clinical application against cerebral ischemia. CNS Neurosci Ther. 2014;20(8):710–6. https://doi.org/10.1111/cns.12288.CrossRefPubMedPubMedCentral

14.

Xia YL, Luo Y, Dong WW. Effect and mechanism of fastigial nucleus stimulation on stroke in rats. J Apoplexy Nerv Dis. 1999;16:3–5.

15.

Miura M, Reis DJ. Cerebellum: a pressor response elicited from the fastigial nucleus and its efferent pathway in brainstem. Brain Res. 1969;13(3):595–9. https://doi.org/10.1016/0006-8993(69)90269-8.CrossRefPubMed

16.

Del Bo A, Sved AF, Reis DJ. Fastigial stimulation releases vasopressin in amounts that elevate arterial pressure. Am J Phys. 1983;244:H687–94.

17.

Del Bo A, Sved AF, Reis DJ. Inhibitory influences from arterial baroreceptors on vasopressin release elicited by fastigial stimulation in rats. Circ Res. 1984;54(3):248–53. https://doi.org/10.1161/01.res.54.3.248.CrossRefPubMed

18.

Golanov EV, Reis DJ. Cerebral cortical neurons with activity linked to central neurogenic spontaneous and evoked elevations in cerebral blood flow. Neurosci Lett. 1996;209(2):101–4. https://doi.org/10.1016/0304-3940(96)12611-2.CrossRefPubMed

19.

Nakai M, Iadecola C, Reis DJ. Global cerebral vasodilation by stimulation of rat fastigial cerebellar nucleus. Am J Phys. 1982;243(2):H226–35. https://doi.org/10.1152/ajpheart.1982.243.2.H226.CrossRef

20.

Glickstein SB, Golanov EV, Reis DJ. Intrinsic neurons of fastigial nucleus mediate neurogenic neuroprotection against excitotoxic and ischemic neuronal injury in rat. J Neurosci. 1999;19(10):4142–54 PMID:10234042.CrossRef

21.

Sui R, Zhang L, Min L, Yuan J, Li X. Cerebellar dysfunction may play an important role in post-stroke depression. Med Hypotheses. 2009;72(6):643–6. https://doi.org/10.1016/j.mehy.2008.11.042.CrossRefPubMed

22.

Baldacara L, Borgio JG, Lacerda AL, Jackowski AP. Cerebellum and psychiatric disorders. Rev Bras Psiquiatr. 2008;30(3):281–9. https://doi.org/10.1590/s1516-44462008000300016.CrossRefPubMed

23.

Fan XL, Dong WW, Yang QD. The prophylactic and curative effects of electrical stimulation of cerebellar fastigial nucleus on vascular dementia in rats. Stroke Nerv Dis. 2004;11:349–52.

24.

Niu LC, Li T, Lei JA, Han Q, Li YX, Zhang BQ, Yan PJ. Effect of cerebellar fastigial nucleus treated by electrical stimulation on 70 patiengts with acute cerebral infarction. Chin J Rehabil Theory Practice. 2005;11:795–6.

25.

Xu X. Application of cerebellar fustigial nucleus electric stimulation on rehabilitation of cerebrovascular diseases. Lab Med Clin. 2010;7:1318–21.

26.

Shen HQ. Cerebral circulation function therapeutic apparatus of the role of the mechanism and clinical effect. Prog Biomed Eng. 2009;30:245–6.

27.

He WY, Li BP, Huang XZ. Clinical observation of treatment of acute cerebral infarction by electrical stimulation of the fastigial nucleus. J Apoplexy Nerv Dis. 2003;20:470.

28.

Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA. PAFS consensus group: CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ. 2016;355:i5239. https://doi.org/10.1136/bmj.i5239.CrossRefPubMedPubMedCentral

29.

Juan Y, Shu O, Jinhe L, Na Y, Yushuang D, Weiwei D, Lanying H, Jian W. Migraine prevention with percutaneous mastoid electrical stimulator: a randomized double-blind controlled trial. Cephalalgia. 2017;37(13):1248–56. https://doi.org/10.1177/0333102416678623.CrossRefPubMed

30.

He L, Wang J, Liu Y, Dong W, Yang H, Luo Y, Xiang T, Luo L. Percutaneous mastoid electrical stimulator alleviates autonomic dysfunction in patients with acute ischemic stroke. Neurol Res. 2018;11:995–1000. https://doi.org/10.1080/01616412.2018.1508548.CrossRef

31.

Paolucci S. Epidemiology and treatment of post-stroke depression. Neuropsychiatr Dis Treat. 2008;4(1):145–17. https://doi.org/10.2147/ndt.s2017.CrossRefPubMedPubMedCentral

32.

Torrisi M, De Cola MC, Buda A, Carioti L, Scaltrito MV, Bramanti P, Manuli A, De Luca R, Calabrò RS. Self-efficacy, Poststroke depression, and rehabilitation outcomes: is there a correlation? J Stroke Cerebrovasc Dis. 2018;27(11):3208–11. https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.07.021.CrossRefPubMed

33.

Ghaffari A, Akbarfahimi M, Rostami HR. Discriminative factors for post-stroke depression. Asian J Psychiatr. 2019;48:101863. https://doi.org/10.1016/j.ajp.2019.101863.CrossRefPubMed

34.

Zhang L, Zhao M, Sui RB. Cerebellar Fastigial nucleus electrical stimulation alleviates depressive-like behaviors in post-stroke depression rat model and potential mechanisms. Cell Physiol Biochem. 2017;41(4):1403–12. https://doi.org/10.1159/000467940.CrossRefPubMed

35.

Schmahman JD, Sherman JC. The cerebellar cognitive affective syndrome. Brain. 1998;121(Pt4):561–79. https://doi.org/10.1093/brain/121.11.2202.CrossRef

36.

Dolan RJ, Bench CJ, Brown RG, Scott LC, Friston KJ, Frackowiak RS. Regional cerebral blood flow abnormalities in depressed patients with cognitive. J Neurol Neurosurg Psychiatry. 1992;55(9):768–73. https://doi.org/10.1136/jnnp.55.9.768.CrossRefPubMedPubMedCentral

37.

Gao W, Wang N, Qiao H. The effects of 5-HT1B receptor subtypes on motor behaviors mediated by cerebellar fastigial nucleus. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2016;32(6):550–4. https://doi.org/10.13459/j.cnki.cjap.2016.06.014.CrossRefPubMed

38.

Runfeng Z, Xia L, Yun zhen C, Ke xin T, Guo-zhong M, Xuan yin H. Effects of cerebellar fastigial nucleus electro-stimulation on release of neurotransmitters in ischemic hearts. Chinese J Clin Rehabil. 2005;9:34–7.

39.

Kimura M, Robinson RG, Kosier JT. Treatment of cognitive impairment after poststroke depression: a double-blind treatment trial. Stroke. 2000;31(7):1482–6. https://doi.org/10.1161/01.str.31.7.1482.CrossRefPubMed

Title: Percutaneous mastoid electrical stimulator improves Poststroke depression and cognitive function in patients with Ischaemic stroke: a prospective, randomized, double-blind, and sham-controlled study
Authors: Taoli Lu
Lanying He
Bei Zhang
Jian Wang
Lili Zhang
Wei Wei Dong
Hao Yang
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Antidepressant Drugs
Stroke
Mood Disorders
Affective Disorder
Antidepressant Drugs
Published in: BMC Neurology / Issue 1/2020
Electronic ISSN: 1471-2377
DOI: https://doi.org/10.1186/s12883-020-01795-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Percutaneous mastoid electrical stimulator improves Poststroke depression and cognitive function in patients with Ischaemic stroke: a prospective, randomized, double-blind, and sham-controlled study

Abstract

Background

Methods

Results

Conclusion

Trial registration

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2020

Polymyoclonus aggravated by neck flexion as the isolated presenting symptom of Hirayama disease: case report

Recovery of mobility function and life-space mobility after ischemic stroke: the MOBITEC-Stroke study protocol

Neuroimaging pattern and pathophysiology of cerebellar stroke-like lesions in MELAS with m.3243A>G mutation: a case report

Injury of Corticospinal tract and Corticoreticular pathway caused by high-voltage electrical shock: a case report

Factors associated with insufficient response to acute treatment of migraine in Japan: analysis of real-world data from the Adelphi Migraine Disease Specific Programme

Abdominal pain due to the spinothalamic tract injury in patients with mild traumatic brain injury: a case report